This website uses cookies

Read our Privacy policy and Terms of use for more information.

Clinical Takeaway
Domain Key Finding Evidence Level
Before treatment Nutritional shortfalls can precede treatment. Preoperative cohorts and national surveys
During treatment Reduced intake makes nutritional assessment and follow-up important. Claims data and a joint society advisory
Act early Persistent vomiting or very poor intake requires prompt attention. Case reports and pharmacovigilance

Your patient's vitamin D is low 6 months into a GLP-1. Did the drug do that? Maybe not. Often the shortfall was there before the first dose.

In Vienna, 1,732 adults were evaluated for bariatric surgery. Their mean BMI was 44. Before anyone operated, 63.2% were low in folate, 9.6% were iron deficient by ferritin, and 97.5% had a vitamin D level below the study's cutoff of 30 ng/mL (75 nmol/L).1 That cutoff is not a universal definition of deficiency, so read the 97.5% with that in mind.2

These were preoperative labs. No operation had yet changed what these patients could eat or absorb. The labs can't tell us who had dieted or been treated before, and they don't mean every patient with obesity is deficient. They do mean you can't assume a clean slate.

Shortfalls like these often come before treatment. When treatment cuts how much someone eats, those shortfalls can get worse unless nutritional care keeps pace. Treatment can also create deficiencies of its own, and a severe shortage of thiamine (vitamin B1) can cause lasting brain injury. None of this is a case against treatment. It's the part of treatment a clinician can get ahead of.

Sponsored · Newsletter brought to you by MicroVitamin+
MicroVitamin+ Mixed Berry tub beside a berry smoothie. Made in USA with imported ingredients. Rated 4.7/5 from 160+ reviews.
The full multivitamin in one scoop, without the megadoses
A lot of multivitamins megadose, with some nutrients at ten times the daily value, which is why your pee often turns bright yellow. MicroVitamin+ helps to fill the gaps in your diet, without the downsides of megadoses.

MicroVitamin was inspired by COSMOS, one of the largest multivitamin trials ever run, with more than 21,000 older adults, where people taking a daily multivitamin did better on memory and thinking tests over two to three years.

You get methylfolate and methyl B12, not the cheaper folic acid and cyanocobalamin. It also has lutein and zeaxanthin for eye health, 5 grams of creatine to support muscle strength, and collagen, which may support skin hydration and elasticity.*
Get 10% off your first MicroVitamin+ order →
Use code DRMIKE at checkout.
I earn a commission on purchases made through this link or code. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

It starts before treatment

Vienna isn't an outlier. In New York, 379 consecutive patients about to have gastric bypass were tested: 68.1% were low in vitamin D, 43.9% in iron, and 29% in thiamine.3 The American Society for Metabolic and Bariatric Surgery's nutrition guideline says it is common for patients presenting for surgery to have at least 1 vitamin or mineral deficiency before the operation.4

Vienna · 1,732 adults evaluated for bariatric surgery
Measure and study cutoff Before surgery
Vitamin D below 75 nmol/L (30 ng/mL) 97.5%
Folate below 5.3 ng/mL 63.2%
Ferritin below 15 μg/L 9.6% (women 11.8%, men 1.5%)
Vitamin B12 below 188 pg/mL 5.1%
Note: The study used a vitamin D cutoff of 30 ng/mL. That is not a universal definition of deficiency, so the 97.5% figure needs to be read in that context. These were preoperative measurements. They don't establish whether participants had previously attempted weight loss or received treatment.

These are surgical candidates, with mean BMIs of 44 and 52, so they sit at the far end. National surveys also find nutritional shortfalls, although the populations and definitions differ.

What the national surveys show

NHANES is the federal survey that examines a representative sample of Americans. Start with what people eat. In one analysis of 18,177 US adults, those with obesity took in about 5% to 12% less of the micronutrients measured than adults with a BMI under 25.5 Low intake isn't confined to obesity. Across 16,110 people aged 2 and older, usual intake from food and supplements combined fell below the estimated average requirement for 70% of the population for vitamin D, 60% for vitamin E, and 45% for magnesium, and later survey cycles found the same pattern.6,7

Eating less than a requirement isn't the same as a low blood level, so a separate analysis of NHANES 2003 to 2006 used biomarkers. In 15,030 people over age 9, with blood levels of vitamins A, B6, B12, C, D, E, and folate plus a check for anemia, 31% were at risk of at least 1 vitamin deficiency or anemia. Among people with obesity, it was 39%.8 Those data are 2 decades old, so I wouldn't read them as current prevalence.

The same surveys found fewer shortfalls among people who reported taking a multivitamin. In the biomarker analysis, 40% of people taking no supplement were at risk of at least 1 vitamin deficiency or anemia, against 14% of people taking a full-spectrum multivitamin and mineral.8 That is a cross-sectional comparison. People who take a multivitamin also tend to eat better, so some of the difference belongs to the person and not the pill. In a second analysis of 10,698 adults, taking a multivitamin on at least 21 of 30 days was associated with far less inadequate intake for most of the 17 nutrients examined. Calcium, magnesium, and vitamin D were the exceptions.9

Why a larger body runs low

This isn't a story about willpower. At least 3 mechanisms are measurable.

Dilution. Vitamin D is fat soluble. In 686 adults, a model based on body weight alone accounted for the lower vitamin D levels seen with obesity: the same amount of vitamin is spread through a larger volume.10 Genetics points the same way. In a study of up to 42,024 people, the genetic analysis supported an effect of higher BMI on lower vitamin D, with little evidence for a meaningful effect in the reverse direction.11

Inflammation. A meta-analysis of 26 studies found 31% higher odds of iron deficiency in people with overweight or obesity (OR 1.31; 95% CI, 1.01 to 1.68). The link showed up in studies that diagnosed deficiency without ferritin and disappeared in studies that used it.12 Ferritin rises with inflammation, so it can read normal while usable iron is low. That's my reading of the split, not the authors' conclusion.

Intake. Calories and micronutrients don't travel together. A diet can supply more energy than a body needs and less magnesium, vitamin D, or vitamin C than it needs. Adequate calories are not adequate nutrition.5

The core claim Nutritional shortfalls often precede obesity treatment. When treatment reduces food intake, those shortfalls can worsen unless nutritional care keeps pace.

Then intake falls

Many effective obesity treatments reduce how much a person eats. Micronutrient intake can fall with it unless the quality of the food holds up.

In the A TO Z trial, women assigned to 4 popular diets cut calories by similar amounts. After 8 weeks, 3 of the 4 diets had moved a significant share of women toward inadequate intake of at least 3 micronutrients. Which ones depended on the diet: thiamine, folate, vitamin C, iron, and magnesium on Atkins; vitamin E, B12, and zinc on Ornish. The fourth diet, Zone, went the other way. Risk of inadequacy fell for vitamins A, E, K, and C, with no significant increase for the other nutrients measured.13 What's on the plate matters more when there's less of it.

A TO Z trial · 4 diets · 8 weeks · similar calorie cuts
Same calorie cut. Different nutrient result.
Micronutrients with a significant shift toward inadequate intake
Atkins
5
LEARN
3
Ornish
3
Zone
0 · risk of inadequacy fell for vitamins A, E, K, and C
Intake from 3-day dietary recalls in women with overweight or obesity. This is intake, not blood levels.

GLP-1 medications reduce appetite for as long as a patient takes them, yet we have little direct data on what that does to nutrient intake. In a cross-sectional study, 69 people taking a GLP-1 medication kept 3-day food records. Average intake fell short of reference values for calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E. B vitamins, zinc, and selenium were adequate.14

The biggest numbers come from billing data. In a claims study of 461,382 adults starting a GLP-1 medication, 22.4% received a diagnosis included in a broad composite of nutritional deficiencies and related complications within a year. The composite included dehydration and muscle-loss codes. Most participants had type 2 diabetes, and the study excluded deficiency diagnoses recorded in the preceding 6 months.15

A newly recorded diagnosis isn't the same as a newly developed deficiency, and neither one proves the drug was the cause. Someone has to test and code before a diagnosis appears, and a 6-month lookback can't rule out a shortfall that was already there. A smaller matched comparison in the same study gives some scale: the broad outcome occurred in 18.6% of people taking a GLP-1 medication with metformin and 16.5% of people taking metformin alone at 1 year. That gap was statistically significant.15 It was also about 2 percentage points. These remain observational findings.

A joint advisory from 4 societies, including the Obesity Medicine Association and The Obesity Society, supports proactive nutritional assessment and management during GLP-1 treatment.16

The emergency not to miss

Thiamine deserves particular urgency because severe deficiency can become a neurological emergency.

Here's the sequence the case reports describe. A patient starts semaglutide. The nausea never settles. For weeks she vomits most days and eats a few bites at a time. The weight comes off fast. Then she becomes confused, she's unsteady on her feet, and her eyes don't move normally. That's Wernicke encephalopathy until proven otherwise. It's brain injury from thiamine deficiency, and it can become permanent if it isn't treated quickly.18 She's a composite drawn from those reports, not one of my patients.

Investigators in Israel searched the FDA's adverse event database and the published literature, then added a case from their own hospital. They counted 15 cases of Wernicke encephalopathy in people on GLP-1 medications, 14 of them reported in 2023 or 2024. In 13 of the 15, the record showed vomiting, appetite loss, weight loss, or malnutrition. Of 11 patients with follow-up, 7 had lasting neurological sequelae. Reports were disproportionate compared with other drugs in the database (reporting odds ratio 2.35; 95% CI, 1.38 to 4.01). That's a reporting signal, not a risk you can quote to a patient.17

Reported Wernicke cases on GLP-1 medications
Of 11 patients with follow-up, 7 had lasting neurological sequelae.
7 with lasting sequelae · 4 others with follow-up
15 cases, most of them from FDA adverse event reports. Reports like these cannot show how often this happens.

A separate review of 6 published semaglutide cases found the same sequence. Some patients progressed to Korsakoff syndrome, a lasting memory disorder, and some died.18 The outcome is severe, and the prevention is cheap.

What these studies can't tell us

1. The prevalence figures aren't interchangeable. Low intake on a diet survey, an abnormal blood marker, anemia, and a diagnosis code on a claim are 4 different things, measured in different populations. Surgical cohorts don't describe everyone with obesity.
2. Looking finds things. In the claims study, patients who saw a dietitian had more deficiency codes, which may reflect more testing, sicker patients, or both. The data can't say how many of those shortfalls predated the first dose.
3. Fewer shortfalls isn't a better outcome. The surveys found fewer shortfalls among people who reported taking a multivitamin. They don't show better health. In 390,124 generally healthy US adults followed for up to 27 years, daily multivitamin use was not associated with lower mortality.19
4. Industry sits close to this literature. The national biomarker analysis was led by scientists at a vitamin manufacturer, and one of the intake analyses by the supplement industry's trade association. The food-record study's authors work for a supplement retailer. The claims study was funded by a nutrition company, and most of its authors are that company's employees. This issue carries a multivitamin sponsor. Weigh all of it accordingly.

My read. None of that argues for ignoring nutrition. It argues for asking about it early and being careful about what the numbers mean.

What I'd take into clinic

  1. Assess nutrition from the first visit. Ask what a typical day of eating looks like, which supplements the patient takes, and whether anything has already narrowed the diet. The same history matters for catching restrictive eating, as I wrote in October. Shortfalls can precede treatment, so don't wait for a complication to ask.1,8

  2. Protect food quality as portions shrink. Less appetite is the point of treatment. As portions get smaller, nutrient-rich foods need to stay on the plate. Bring in a dietitian when intake becomes restricted or difficult.16,20

  3. Test with a reason. Let the history, symptoms, diet, and medications guide what you order. Ferritin alone can miss iron deficiency when inflammation is high, so add transferrin saturation.12 Keep B12 in mind for patients on metformin, which carries a B12 warning on its label. Obesity alone isn't a reason to check vitamin D: the Endocrine Society suggests against routine testing in adults with obesity who have no other established indication.2

  4. Treat identified deficiencies and monitor the response. Supplements can help when intake is thin. An established deficiency may need targeted replacement, with repeat testing to confirm it worked. When vitamin D replacement is indicated, adjust the dose for body size.10

  5. Act early on vomiting or very poor intake. Persistent vomiting or very poor intake warrants prompt clinical assessment, including hydration, electrolytes, and thiamine risk. Confusion, trouble walking, or abnormal eye movements require emergency evaluation. Suspected Wernicke encephalopathy needs immediate parenteral thiamine without waiting for a blood level.18

  6. Reassess on the patient's timeline, not the calendar's. Base follow-up on baseline abnormalities, symptoms, dietary restriction, and treatment response. The joint advisory recommends ongoing reassessment of intake, hydration, and nutrient status during treatment.16

If you're the one taking the medication: tell your prescriber right away if you're vomiting persistently or barely eating, and get emergency care for confusion, trouble walking, or new double vision. Thiamine works best before the damage sets in.18

The bottom line

Nutrition belongs in the first visit, not the first complication. Ask what the patient is eating, revisit it as appetite changes, and act early when intake becomes inadequate. That should be part of routine obesity care.

One question before you go. Your answer takes one click and helps me decide what to write next.

At Vineyard, our clinicians treat obesity as the chronic disease it is. See how Vineyard approaches obesity care →

Following the latest GLP-1 trials? Explore the trial tracker →

Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice. He is a consultant to Viking Therapeutics and provides research consulting to Novo Nordisk, which makes semaglutide, discussed in this article. This issue includes a paid sponsorship for MicroVitamin+, and the author earns a commission on purchases made through its link or code. This article is educational and is not individualized medical advice. Talk with your own clinician before making changes to your care.

REFERENCES

1. Krzizek EC, Brix JM, Herz CT, Kopp HP, Schernthaner GH, Schernthaner G, et al. Prevalence of micronutrient deficiency in patients with morbid obesity before bariatric surgery. Obes Surg. 2018;28(3):643-648. doi:10.1007/s11695-017-2902-4

2. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290

3. Flancbaum L, Belsley S, Drake V, Colarusso T, Tayler E. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. J Gastrointest Surg. 2006;10(7):1033-1037. doi:10.1016/j.gassur.2006.03.004

4. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical weight loss patient 2016 update: micronutrients. Surg Obes Relat Dis. 2017;13(5):727-741. doi:10.1016/j.soard.2016.12.018

5. Agarwal S, Reider C, Brooks JR, Fulgoni VL. Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001-2008. J Am Coll Nutr. 2015;34(2):126-134. doi:10.1080/07315724.2014.901196

6. Fulgoni VL, Keast DR, Bailey RL, Dwyer J. Foods, fortificants, and supplements: where do Americans get their nutrients? J Nutr. 2011;141(10):1847-1854. doi:10.3945/jn.111.142257

7. Wallace TC, McBurney M, Fulgoni VL. Multivitamin/mineral supplement contribution to micronutrient intakes in the United States, 2007-2010. J Am Coll Nutr. 2014;33(2):94-102. doi:10.1080/07315724.2013.846806

8. Bird JK, Murphy RA, Ciappio ED, McBurney MI. Risk of deficiency in multiple concurrent micronutrients in children and adults in the United States. Nutrients. 2017;9(7):655. doi:10.3390/nu9070655

9. Blumberg JB, Frei BB, Fulgoni VL, Weaver CM, Zeisel SH. Impact of frequency of multi-vitamin/multi-mineral supplement intake on nutritional adequacy and nutrient deficiencies in U.S. adults. Nutrients. 2017;9(8):849. doi:10.3390/nu9080849

10. Drincic AT, Armas LA, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring). 2012;20(7):1444-1448. doi:10.1038/oby.2011.404

11. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;10(2):e1001383. doi:10.1371/journal.pmed.1001383

12. Zhao L, Zhang X, Shen Y, Fang X, Wang Y, Wang F. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16(12):1081-1093. doi:10.1111/obr.12323

13. Gardner CD, Kim S, Bersamin A, Dopler-Nelson M, Otten J, Oelrich B, et al. Micronutrient quality of weight-loss diets that focus on macronutrients: results from the A TO Z study. Am J Clin Nutr. 2010;92(2):304-312. doi:10.3945/ajcn.2010.29468

14. Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr. 2025;12:1566498. doi:10.3389/fnut.2025.1566498

15. Butsch WS, Sulo S, Chang AT, Kim JA, Kerr KW, Williams DR, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars. 2025;15:100186. doi:10.1016/j.obpill.2025.100186

16. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023

17. Lev D, Leibowitz A, Lang A, Shlomai G, Twig G, Eden-Friedman Y, et al. Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: a pharmacovigilance study and literature review. Clin Nutr. 2026;57:106571. doi:10.1016/j.clnu.2025.106571

18. Bidesie J, Oudman E. Wernicke's encephalopathy following semaglutide treatment for obesity: a systematic PRISMA review of case-based evidence. Obesity (Silver Spring). 2026;34 Suppl 2:64-69. doi:10.1002/oby.70256

19. Loftfield E, O'Connell CP, Abnet CC, Graubard BI, Liao LM, Beane Freeman LE, et al. Multivitamin use and mortality risk in 3 prospective US cohorts. JAMA Netw Open. 2024;7(6):e2418729. doi:10.1001/jamanetworkopen.2024.18729

20. Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring). 2024;32(9):1613-1631. doi:10.1002/oby.24067

Evidence-based obesity medicine, twice a week. No hype, no telehealth grifts.